1. Home
  2. NTRA vs STT Comparison

NTRA vs STT Comparison

Compare NTRA & STT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • STT
  • Stock Information
  • Founded
  • NTRA 2003
  • STT 1792
  • Country
  • NTRA United States
  • STT United States
  • Employees
  • NTRA N/A
  • STT N/A
  • Industry
  • NTRA Medical Specialities
  • STT Major Banks
  • Sector
  • NTRA Health Care
  • STT Finance
  • Exchange
  • NTRA Nasdaq
  • STT Nasdaq
  • Market Cap
  • NTRA 21.7B
  • STT 25.8B
  • IPO Year
  • NTRA 2015
  • STT N/A
  • Fundamental
  • Price
  • NTRA $163.02
  • STT $111.04
  • Analyst Decision
  • NTRA Strong Buy
  • STT Buy
  • Analyst Count
  • NTRA 16
  • STT 11
  • Target Price
  • NTRA $193.50
  • STT $116.18
  • AVG Volume (30 Days)
  • NTRA 1.7M
  • STT 1.7M
  • Earning Date
  • NTRA 08-07-2025
  • STT 10-14-2025
  • Dividend Yield
  • NTRA N/A
  • STT 3.03%
  • EPS Growth
  • NTRA N/A
  • STT 67.51
  • EPS
  • NTRA N/A
  • STT 8.92
  • Revenue
  • NTRA $1,964,250,000.00
  • STT $13,323,000,000.00
  • Revenue This Year
  • NTRA $19.98
  • STT $6.71
  • Revenue Next Year
  • NTRA $16.16
  • STT $3.40
  • P/E Ratio
  • NTRA N/A
  • STT $12.45
  • Revenue Growth
  • NTRA 44.38
  • STT 10.97
  • 52 Week Low
  • NTRA $110.57
  • STT $72.81
  • 52 Week High
  • NTRA $183.00
  • STT $114.28
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 65.28
  • STT 54.00
  • Support Level
  • NTRA $152.62
  • STT $110.01
  • Resistance Level
  • NTRA $161.92
  • STT $111.95
  • Average True Range (ATR)
  • NTRA 6.11
  • STT 1.96
  • MACD
  • NTRA 3.42
  • STT -0.21
  • Stochastic Oscillator
  • NTRA 93.78
  • STT 53.31

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About STT State Street Corporation

State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $47 trillion in assets under custody and administration and $4.7 trillion assets under management as of Dec. 31, 2024, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.

Share on Social Networks: